Vandortuzumab vedotin
Vandortuzumab Vedotin
Vandortuzumab Vedotin (pronunciation: van-dor-tu-zu-mab ve-do-tin) is a monoclonal antibody-drug conjugate used in the treatment of various types of cancer.
Etymology
The name "Vandortuzumab Vedotin" is derived from the combination of "Vandortuzumab", the monoclonal antibody, and "Vedotin", the cytotoxic drug. The prefix "Vandor" is a unique identifier for the antibody, while "tuzumab" is a common suffix for monoclonal antibodies. "Vedotin" is a term used to describe a class of cytotoxic drugs.
Usage
Vandortuzumab Vedotin is used in the treatment of various types of cancer, including non-Hodgkin lymphoma and Hodgkin lymphoma. It works by binding to a specific protein on the surface of cancer cells and delivering a cytotoxic drug directly to the cells, causing them to die.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Cytotoxic drug: A medication that kills cells, especially cancer cells.
- Non-Hodgkin lymphoma: A type of cancer that originates in the lymphatic system, the body's disease-fighting network.
- Hodgkin lymphoma: A type of lymphoma, which is a cancer of the lymphatic system.
External links
- Medical encyclopedia article on Vandortuzumab vedotin
- Wikipedia's article - Vandortuzumab vedotin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski